Skip to main content

Table 1 Sample dilution and validation of immunosorbent assay

From: Bevacizumab suppressed degenerative changes in articular cartilage explants from patients with osteoarthritis of the knee

Biomarkers

Manufacture/catalog#

Dilution

Intra-assay CV (%)

Inter-assay CV (%)

MMP-2

R&D/MMP200

1:10

5.7

8.4

MMP-3

R&D/DMP300

1:1000

6.3

8.5

MMP-9

R&D/DMP900

1:50

4.4

10.1

MMP-13

R&D/DY511

1:10

3.5

7.3

TIMP-1

R&D/DTM100

1:100

3.7

6.8

TIMP-2

R&D/DTM200

1:100

6.4

11.2

COMP

R&D/DCMP0

1:500

2.8

5.8

  1. CV Coefficient of variation; MMP Matrix metalloproteinase; TIMP Tissue inhibitor of metalloproteinase; COMP Cartilage oligomeric matrix protein